Zobrazeno 1 - 10
of 574
pro vyhledávání: '"extended half-life"'
Autor:
Orhan Yilmaz, Tiago Torres
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 9, Pp 2393-2406 (2024)
Abstract Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by intense pruritus and eczematous lesions, significantly impacting physical health and quality of life. The pathogenesis of AD involves genetic predisposition, imm
Externí odkaz:
https://doaj.org/article/f1e28122a36b41758fc211c60f146520
Autor:
Giovanni Di Minno, Gaia Spadarella, Ilenia Lorenza Calcaterra, Giancarlo Castaman, Paolo Simioni, Raimondo De Cristofaro, Cristina Santoro, Flora Peyvandi, Matteo Di Minno
Publikováno v:
Bleeding, Thrombosis and Vascular Biology, Vol 3, Iss 2 (2024)
Despite major advances in prophylaxis, no repeated dosing regimen with currently employed extended-half-life or non-factor products replaces the advantages of a long-term cure in persons with severe congenital hemophilia A and B (HA, HB). They indeed
Externí odkaz:
https://doaj.org/article/2caedf3070ec4fd3a6ae3d0ea3de9d4c
Autor:
Ángeles Palomo Bravo, Rosario Prieto Bonilla, Daniel Bardan Rebollar, Francisco José López‐Jaime, Ihosvany Fernández‐Bello
Publikováno v:
Clinical Case Reports, Vol 12, Iss 8, Pp n/a-n/a (2024)
Key Clinical Message Recommendations advise factor IX desensitization before immune tolerance induction in severe hemophilia B, supported by immunosuppression. A child with inhibitor and anaphylaxis to factor IX showed successful immunosuppression‐
Externí odkaz:
https://doaj.org/article/06613864f4aa4d3bb9558fdb0544fad6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Bleeding, Thrombosis and Vascular Biology, Vol 3, Iss 1 (2024)
Although the use of prophylaxis regimens with prolonged half-life factors is now widespread in the world of hemophilia A, there is a lack of real-life evidence on the impact of these products on joint health, adherence, and quality of life of patient
Externí odkaz:
https://doaj.org/article/642f684552ae4a348e003b6ca66d2792
Publikováno v:
Hematology, Vol 28, Iss 1 (2023)
ABSTRACTStandard FIX prophylaxis for PWHB require frequent injections, which has led to the development of extended half-life products like rIX-FP (albutrepenonacog alfa) that has shown good efficacy in clinical studies. This ambispective study aims
Externí odkaz:
https://doaj.org/article/665a1b2ad7d044f5965a3410638193cf
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 16, Pp 3109-3116 (2022)
Samantha Pasca,1,2 Ezio Zanon3 1Biomedical Sciences Department (DSB) - Padua University Hospital, Padua, Italy; 2Medicine Department (DIMED) - Padua University Hospital, Padua, Italy; 3Hemophilia Center, General Medicine - Padua University Hospital,
Externí odkaz:
https://doaj.org/article/af2e93a15f2e4271984378437e8cf7b2
Publikováno v:
Patient Preference and Adherence, Vol Volume 15, Pp 2443-2454 (2021)
Robert Klamroth,1 Kingsley Hampton,2 Sonata Saulyte Trakymienė,3 Lars Korsholm,4 Manuel Carcao5 1Department of Internal Medicine, Hemophilia Treatment Centre, Vivantes Klinikum im Friedrichshain, Berlin, Germany; 2Department of Cardiovascular Scienc
Externí odkaz:
https://doaj.org/article/2c960f49b0f844b0a10151a59a239b6a
Publikováno v:
Journal of Biomedical Science, Vol 28, Iss 1, Pp 1-13 (2021)
Abstract Mainstay haemophilia treatment, namely intravenous factor replacement, poses several clinical challenges including frequent injections due to the short half-life of recombinant factors, intravenous administration (which is particularly chall
Externí odkaz:
https://doaj.org/article/5e718dda607841c981c6a76f2e806556